MYCN and neoplasm: Taken together, these results suggest that R788 has a capacity to remodel the immune “cold” tumors into immune “hot” tumors by reprogramming the macrophages and together with anti-PDL1mAb and radiation it can regress tumor growth in high-risk MYCN-A NB (Figure 7E).